ProCE Banner Series

Next-Generation Approaches for Relapsed/Refractory Multiple Myeloma: A Focus on Novel Therapeutic Targets and Pathways

Join us for this live symposium in conjunction with EHA 2025 in which an expert panel will discuss targeting protein degradation pathways for treating patients with relapsed/refractory multiple myeloma. Sign up now!

Please note: You must be registered for the EHA 2024 Congress to attend this symposium in person or virtually. You may register at: https://ehaweb.org/congress/eha2025-congress/register-for-eha2025/

  AMA
Who Should Attend

This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma.

All Events

Next-Generation Approaches for Relapsed/Refractory Multiple Myeloma: A Focus on Novel Therapeutic Targets and Pathways

Upcoming Events

June

12

2025

7:45 AM - 9:30 AM Central European Time (CET)

In-person

Allianz MiCo • Milano Convention Centre, Piazzale Carlo Magno, 1/Gate 16, 20149 Milano MI, Italy

8:00 AM - 9:30 AM Central European Time (CET)

Virtual

Topics

Hematologic malignancies, myeloma

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with multiple myeloma. 

Target Audience
This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Describe the role and rationale for novel immunomodulatory mechanisms of action that are still under investigation as therapeutic options for patients with relapsed/refractory MM who may be resistant to previous therapies
  • Evaluate the efficacy data as well as safety and tolerability profiles of investigational agents that target protein degradation pathways in MM treatment, including the potential clinical application in triple-class exposed MM
  • Identify eligible patients with r/r MM for enrollment on ongoing clinical trials evaluating novel therapies targeting novel pathways with awareness of potential disparities in clinical trial enrollment in this patient population

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Bristol-Myers Squibb.